GlassScriptPhysician profile
Clement Y Chu
NPI 1063588762
$1,726.40
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $114 · 2021: $518 · 2022: $737.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.88 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $253.30 | 2022 | |
| Intercept Pharmaceuticals, INC. | $227.31 | 2019-2022 | |
| Gilead Sciences, INC. | $210.92 | 2020-2021 | |
| Csa Medical, INC | $150.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $123.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.